Axogen, Inc. — Director's Dealing 2018

Dec 31, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2018-12-27

Reporting Person: DeVinney Erick Wayne (VP, Clinical&Translational Sc)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-27	Employee Stock Option (right to purchase)	$19.17	A	11900	Acquired	2028-12-27	Common Stock (11900)	Direct
2018-12-27	Restricted Stock Units	$	A	3000	Acquired		Common Stock (3000)	Direct

Footnotes

F1: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.